<DOC>
	<DOCNO>NCT00698386</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy oral Zinc administration new smear positive pulmonary tuberculosis patient . Evidence available suggest zinc deficiency rapidly diminish antibody- cell-mediated immune response human animal render individual susceptible variety pathogen . This micronutrient also find useful treatment lung tuberculosis limit number patient . We conduct study category-I patient ( As per World Health Organization , Geneva classification tuberculosis ) lung tuberculosis see efficacy also see change immunological parameter .</brief_summary>
	<brief_title>Efficacy Oral Zinc Administration Adjunct Therapy New Pulmonary Tuberculosis ( Category I ) Patients</brief_title>
	<detailed_description>Malnutrition commonly observe patient pulmonary tuberculosis . There report claim patient active pulmonary tuberculosis malnourish indicate diminished visceral protein , anthropometric index , micronutrient status . Zinc play role protect cell damaging effect free radical . Zinc supplementation show prevent pulmonary pathology due hypoxia-induced lung damage rat . The role zinc faster sputum smear conversion yet study . However , report confirms , vitro cellular kill tubercle bacillus macrophage zinc supplementation . We investigate oral zinc supplement efficacy TB patient `` double-blind placebo-controlled randomized clinical trial '' fashion . We conduct trial Category-I pulmonary TB Patients ( per RNTCP , Ministry Health Family Welfare , Govt.of India ) , assess outcome form clinical improvement , sputum conversion immunological parameter . This multi-centric trial sponsor Department Biotechnology , Ministry Science Technology , Govt . India . Supplements placebo prepared Cadila pharmaceutical Ltd. , India , form tablet . Each micronutrient tablet contain 50mg zinc ( zinc sulphate ) lactose matrix . The placebo consist lactose alone . Supplement placebo capsule indistinguishable appearance externally internally . In clinical trial one tablet zinc oral supplement give everyday entire course line directly observe treatment , short-course ( DOTS ) strategy recommend World Health Organization .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Micronutrients</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>Newly diagnose sputum smear positive pulmonary TB case . Hypersensitivity Category I antiTB drug . Category II pulmonary TB multidrug resistant TB ( MDRTB ) . patient . Presence secondary immunodeficiency state : HIV , organ transplantation , diabetes mellitus , malignancy , treatment corticosteroid Hepatitis B C positivity . Patients extrapulmonary TB and/or patient require surgical intervention . Currently receive cytotoxic therapy , receive within last 3 month . Pregnancy lactation . Patients known seizure disorder . Patients know symptomatic cardiac disease , arrhythmias coronary artery disease . Patients abnormal renal function ( serum creatinine 2 mg/dl 2+ proteinuria ) . Patients abnormal hepatic function ( serum bilirubin &gt; 1.5 mg/dl ; AST , ALT , SAP 1.5 time upper limit normal ; PT = 1.3 time control ) . Patients hematological abnormality ( WBC lesser equal to3000/ cubic mm ; platelet less equal 100,000/cubic mm ) . Seriously ill moribund patient complication : low lung reserve , mark tachypnoea , chronic corpulmonale , congestive cardiac failure , BMI &lt; 15 , severe hypoalbuminemia . Patients unable survive less 6 month . Patients unable comply treatment regimen . Patients history alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Micronutrient Zinc</keyword>
	<keyword>Category I PTB</keyword>
	<keyword>RNTCP</keyword>
	<keyword>DOTS</keyword>
	<keyword>Sputum smear conversion</keyword>
	<keyword>Reduced relapse</keyword>
	<keyword>Immunopathogenesis</keyword>
	<keyword>Category-I</keyword>
</DOC>